Cethromycin - AliquantumRx
Latest Information Update: 11 Oct 2024
Price :
$50 *
At a glance
- Originator AliquantumRx
- Class Antibacterials; Antimalarials; Ketolides
- Mechanism of Action Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Malaria
Most Recent Events
- 28 Aug 2024 Aliquantumrx has patents pending for 'Salts and polymorphs of cethromycin for the treatment of disease' in USA
- 28 Aug 2024 AliquantumRx announces intention to submit IND for Malaria in 2024 (AliquantumRx pipeline, August 2024)
- 28 Aug 2024 AliquantumRx plans a phase II trial for Malaria in 2024 (AliquantumRx pipeline, August 2024)